Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J.B. Williams making Cepacol ColdCare zinc lozenges cold claim despite "courtesy letter".

This article was originally published in The Tan Sheet

Executive Summary

J.B. WILLIAMS CEPACOL COLDCARE ZINC LOZENGES COLD CLAIM will remain on packaging, the firm said in response to an Oct. 9 "courtesy letter" from FDA. On Sept. 25, the firm notified FDA it would be marketing the dietary supplement Cepacol ColdCare Zinc Acetate Lozenges with the structure/function claim, "Taken as a dietary supplement, Cepacol ColdCare helps promote general well-being during the cold season." FDA states the claim and the product name, "taken together, suggest that it is intended to treat, mitigate, or prevent a disease, namely the common cold," and the product is thus an unapproved new drug.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel